Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 6, 2017Journal of Surgical OncologyOpen Access

Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas

View Full Paper
Ask AI
Bookmark
Share

Authors

CNConstantinos NastosNational and Kapodistrian University of AthensVCVincent CheungJohn Radcliffe HospitalCTChristos ToumpanakisRoyal Free London NHS Foundation Trust

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nastos et al. (2017) studied this question.

synapsesocial.com/papers/6a8a72df0e1a8f7244fd7917https://doi.org/10.1002/jso.24553
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<sup>111</sup>In-Octreotide Is Superior to <sup>123</sup>I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas2008 · 115 citations
  2. 2<sup>123</sup>I‐metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra‐adrenal phaeochromocytomas: CT and MRI correlation2008 · 128 citations
  3. 3Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)2012 · 73 citations